Atherosclerosis
Volume 197, Issue 2 , Pages 564-571 , April 2008

Cyclophilin A differentially activates monocytes and endothelial cells: Role of purity, activity, and endotoxin contamination in commercial preparations

  • Sravan K. Payeli

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • ,
  • Cordelia Schiene-Fischer

      Affiliations

    • Max Planck Research Unit for Enzymology of Protein Folding, Halle an der Saale, Germany
    • ,
  • Jan Steffel

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland
    • ,
  • Giovanni G. Camici

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • ,
  • Izabela Rozenberg

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • ,
  • Thomas F. Lüscher

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland
    • ,
  • Felix C. Tanner

      Affiliations

    • Cardiovascular Research, Institute of Physiology, University of Zurich, Switzerland
    • Center for Integrative Human Physiology, University of Zurich, Switzerland
    • Cardiology, Cardiovascular Center, University Hospital Zurich, Zurich, Switzerland
    • Corresponding Author InformationCorresponding author at: Cardiovascular Research, Institute of Physiology, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland. Tel.: +41 44 6356469; fax: +41 44 6356827.

Received 14 May 2007 ,Revised 19 August 2007 ,Accepted 20 August 2007.

References 

  1. Wang P, Heitman J. The cyclophilins. Genome Biol. 2005;6(7):226
  2. Ryffel B, Woerly G, Greiner B, et al. Distribution of the cyclosporine binding protein cyclophilin in human tissues. Immunology. 1991;72(3):399–404
  3. Fischer G, Wittmann-Liebold B, Lang K, Kiefhaber T, Schmid FX. Cyclophilin and peptidyl-prolyl cis-trans isomerase are probably identical proteins. Nature. 1989;337(6206):476–478
  4. Piotukh K, Gu W, Kofler M, et al. Cyclophilin A binds to linear peptide motifs containing a consensus that is present in many human proteins. J Biol Chem. 2005;280(25):23668–23674
  5. Fruman DA, Klee CB, Bierer BE, Burakoff SJ. Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A. Proc Natl Acad Sci USA. 1992;89(9):3686–3690
  6. Clardy J. The chemistry of signal transduction.. Proc Natl Acad Sci USA. 1995;92(1):56–61
  7. Sherry B, Yarlett N, Strupp A, Cerami A. Identification of cyclophilin as a proinflammatory secretory product of lipopolysaccharide-activated macrophages. Proc Natl Acad Sci USA. 1992;89(8):3511–3515
  8. Kim SH, Lessner SM, Sakurai Y, Galis ZS. Cyclophilin A as a novel biphasic mediator of endothelial activation and dysfunction. Am J Pathol. 2004;164(5):1567–1574
  9. Suzuki J, Jin ZG, Meoli DF, Matoba T, Berk BC. Cyclophilin A is secreted by a vesicular pathway in vascular smooth muscle cells. Circ Res. 2006;98(6):811–817
  10. Jin ZG, Lungu AO, Xie L, et al. Cyclophilin A is a proinflammatory cytokine that activates endothelial cells. Arterioscler Thromb Vasc Biol. 2004;24(7):1186–1191
  11. Camici GG, Steffel J, Akhmedov A, et al. Dimethyl sulfoxide inhibits tissue factor expression, thrombus formation, and vascular smooth muscle cell activation: a potential treatment strategy for drug-eluting stents. Circulation. 2006;114(14):1512–1521
  12. Steffel J, Latini RA, Akhmedov A, et al. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005;112(13):2002–2011
  13. Steffel J, Akhmedov A, Greutert H, Luscher TF, Tanner FC. Histamine induces tissue factor expression: implications for acute coronary syndromes. Circulation. 2005;112(3):341–349
  14. Steffel J, Hermann M, Greutert H, et al. Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation. 2005;111(13):1685–1689
  15. Weiss S, Frischknecht K, Greutert H, et al. Different migration of vascular smooth muscle cells from human coronary artery bypass vessels. Role of Rho/ROCK pathway. J Vasc Res. 2007;44(2):149–156
  16. Gao B, Tsan MF. Endotoxin contamination in recombinant human heat shock protein 70 (Hsp70) preparation is responsible for the induction of tumor necrosis factor alpha release by murine macrophages. J Biol Chem. 2003;278(1):174–179
  17. Billich A, Winkler G, Aschauer H, Rot A, Peichl P. Presence of cyclophilin A in synovial fluids of patients with rheumatoid arthritis. J Exp Med. 1997;185(5):975–980
  18. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):868–874
  19. Pathak SK, Basu S, Bhattacharyya A, et al. TLR4-dependent NF-kappaB activation and mitogen- and stress-activated protein kinase 1-triggered phosphorylation events are central to Helicobacter pylori peptidyl prolyl cis-, trans-isomerase (HP0175)-mediated induction of IL-6 release from macrophages. J Immunol. 2006;177(11):7950–7958
  20. Drew AF, Tipping PG. Cyclosporine treatment reduces early atherosclerosis in the cholesterol-fed rabbit. Atherosclerosis. 1995;116(2):181–189
  21. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol. 1992;2(8):1291–1297
  22. Redondo-Horcajo M, Lamas S. Oxidative and nitrosative stress in kidney disease: a case for cyclosporine A. J Nephrol. 2005;18(4):453–457
  23. Gamba A, Mamprin F, Fiocchi R, et al. The risk of coronary artery disease after heart transplantation is increased in patients receiving low-dose cyclosporine, regardless of blood cyclosporine levels. Clin Cardiol. 1997;20(9):767–772
  24. Gamba A, Mammana C, Fiocchi R, Iamele L, Mamprin F. Cyclosporine and graft coronary artery disease after heart transplantation. Compr Ther. 2000;26(2):121–126
  25. Tanaka M, Mokhtari GK, Balsam LB, et al. Cyclosporine mitigates graft coronary artery disease in murine cardiac allografts: description and validation of a novel fully allogeneic model. J Heart Lung Transplant. 2005;24(4):446–453

PII: S0021-9150(07)00531-X

doi: 10.1016/j.atherosclerosis.2007.08.025

Atherosclerosis
Volume 197, Issue 2 , Pages 564-571 , April 2008

Article Tools

* Image Usage & Resolution